Global Erdosteine Market to accrue US $160 Mn by 2025

August 07, 2019


Global erdosteine market is presumed to surpass US $160 million by the year 2025, according to the latest research available at Market Study Report LLC, report provides extensively data on market share, growth, trends and forecasts for the period 2019-2025.
 

The increasing instances of smoking, immune disorders, and pollen & dirt allergies cause infections leading to excessive mucus production. Common cold, cough, and bronchitis are few of the common respiratory problems which can be cured using drugs manufactured from erdosteine which in turn drives the global erdosteine market growth.
 

Many developing economies including India, Indonesia, and China are witnessing an increase in smoking due to lifestyle changes and growing disposable incomes. Smoking is cited to cause over production of mucus leading to chronic bronchitis and cough. The irritation in throat and thickening of mucus are a result of damaged cilia due to inhaled smoke, hindering the healthy movement of mucus to the throat and accumulation in bronchioles. Erdosteine, having antibacterial and mucolytic properties, is used for manufacturing medicines which control the production of mucus, thus stimulating the erdosteine market growth, cites the study.
 

The application of erdosteine in pharmaceutical industry has boosted the market growth in 2018 and its share was valued at US $45 million. The presence of contaminants such as combustion particles, ammonia, nitrates, nitrogen & sulphur oxides, and ground level ozone in the air trigger inflation in the larynx and pharynx causing varied respiratory ailments including asthma, emphysema, chronic obstructive pulmonary disorder, and congestions,  which in turn, promotes the demand for erdosteine.
 

As cited in the report, the erdosteine market is anticipated to witness significant demand from research institutions demonstrating 5.5% gains by the year 2025. New advancements in medicinal technology are focussed on evolving pharmaceutical drug delivery system and reducing the manufacturing costs. Reputed institutions of Europe and U.S. including Standford Medicine, Yale School of Medicine, John Hopkins University, and Harvard Medical School are investing heavily to quantify & qualify the efficacy of erdosteine in various diseases, instigating the growth of endorsteine market.
 

Request sample copy of this Report@ https://www.marketstudyreport.com/request-a-sample/2105466/
 

The chief contenders of the endorsteine market are undertaking strict research to evolve economical processes to manufacture erdosteine from cysteine and putting efforts to produce regulatory approved products while widening the market over the geographical landscape. The companies profiled in the report include Altitair Pharmaceuticals, Recipharm AB, Hikma Pharmaceuticals, Hanmi Pharmaceuticals, Delta Finochem, and Taj Pharmaceuticals.
 

The report also encompasses the comprehensive insights about the market trends, segmentation, geographical landscape, and economic analysis impacting the erdosteine market over 2019 -2025.


Frequently Asked Questions (FAQ) :

Rising prevalence of common respiratory ailments such as cough, cold, and bronchitis is fueling the growth of erdosteine market. Erdosteine is widely used in manufacturing drugs to treat symptoms of excessive mucus production caused by immune disorders, allergies, and smoking. It is highly preferred by pharmaceutical manufacturers owing to its mucolytic and antibacterial properties, which in turn is augmenting the market share.
Erdosteine market from bronchitis segment is expected to see considerable growth in the coming years, owing to increasing trend of smoking in emerging economies such as India, China, and Indonesia, due to rising disposable income and liberal lifestyle. Chronic smoking habits can lead to excessive mucus production which is linked to chronic diseases including smokers cough and chronic bronchitis. Hence, increasing cases of bronchitis will boost the demand for erdosteine.
Pharmaceutical segment was worth USD 45 million in 2018 and is anticipated to see substantial growth over the analysis period. The growth can be affixed to rising incidences of chronic respiratory disease, on account of poor air quality consisting of harmful elements such as nitrogen & sulphur oxides, nitrates, combustion particles, ammonia, and ground level ozone.
Major players of erdosteine market include Recipharm AB, Altitair Pharmaceuticals, Delta Finochem, Hanmi Pharmaceuticals, Hikma Pharmaceuticals, and Taj Pharmaceuticals. These companies are actively focusing on R&D activities to improve the product quality and to discover new ways to manufacture edosteine from cysteine to lower the manufacturing cost.
Chat with us